Low Prevalence of Mild Alpha-1-Antitrypsin Deficiency in Hospitalized COVID-19-Patients

INTRODUCTION: Alpha-1-antitrypsin (AAT) has been shown to inhibit SARS-CoV-2 cell entry and suggested as a therapeutic agent for COVID-19. Furthermore, epidemiological association of high prevalence of Alpha-1-antitrypsin deficiency (AATD) and regional severity of COVID-19-impact has been hypothesiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Nygren, David, Mölstad, Ulrica, Thulesius, Hans, Hillman, Magnus, Broman, Lars Mikael, Tanash, Hanan, Landin-Olsson, Mona, Rasmussen, Magnus, Thunander, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250346/
https://www.ncbi.nlm.nih.gov/pubmed/35789772
http://dx.doi.org/10.2147/IJGM.S370434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250346/
https://www.ncbi.nlm.nih.gov/pubmed/35789772
http://dx.doi.org/10.2147/IJGM.S370434

Ejemplares similares